Page 26 - Read Online

Page 8 of 10 Burlone et al. Hepatoma Res 2020;6:3 I http://dx.doi.org/10.20517/2394-5079.2019.37

Availability of data and materials
Raw data are available upon request.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Being a retrospective analysis of anonymized data of patients treated in standard clinical practice, no
ethical committee approval was required. However, all patients gave written informed consent for their
participation to the study, which was conducted in strict accordance to the Principles of the Declaration of
Helsinki.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol
2018;69:461-511.
2. World Health Organization. Global hepatitis report, 2017. 2017.
3. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
4. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayho MA, et al. The burden of primary liver cancer and underlying etiologies from 1990
to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
5. Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, et al. Does interferon-free direct-acting antiviral therapy for hepatitis c after curative
treatment for hepatocellular carcinoma lead to unexpected recurrences of hcc? A multicenter study by the Japanese red cross hospital liver
study group. PLoS One 2018;13:e0194704.
6. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al. Effect of interferon-based and -free therapy on early occurrence and
recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.
7. Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma
recurrence rate in cirrhotic patients with chronic hepatitis C. Liver Int 2017;37:1122-7.
8. Su F, Ioannou GN. Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis 2019;13:6-12.
9. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, et al. Hepatocellular carcinoma decreases the chance of successful
hepatitis C virus therapy with direct-acting antivirals. J Hepatol 2017;66:1173-81.
10. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-94.
11. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology
1994;20:15-20.
12. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
13. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, et al. EASL clinical practice guidelines: management of hepatocellular
carcinoma. J Hepatol 2018;69:182-236.
14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-700.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
16. Liu P, Xie SH, Hu S, Cheng X, Gao T, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States.
Oncotarget 2017;8:68131-7.
17. Burlone ME, Pedrinelli AR, Giarda P, Minisini R, Pirisi M. Influence of age on sex-related differences among patients with hepatitis C.
Eur J Gastroenterol Hepatol 2016;28:1100-1.
18. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a
multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21.
19. Nasta P. “Immune activation, aging and gender” and progression of liver disease. Acta Biomed 2011;82:115-23.